Literature DB >> 32048282

Reversible Lesion of the Corpus Callosum in a Patient With Migraine With Aura: A Case Study.

Richard Lewis1, Armando Ruiz2, Teshamae Monteith3.   

Abstract

OBJECTIVE: To describe a patient with migraine with aura (MWA) who was found to have a reversible lesion of the corpus callosum.
BACKGROUND: Reversible lesions of the splenium of the corpus callosum are well-described clinical-radiographic phenomena, which have been associated with a wide array of disease states, including epilepsy, demyelinating disease, infection, and metabolic derangements. There have been few case reports in the literature to date of these lesions associated with migraine headache. DESIGN/
METHODS: A case report.
RESULTS: A 41 year-old female with a history of migraine with visual aura presented with headache associated with left-sided sensorimotor deficits. Routine laboratory tests were within normal limits. An electroencephlogram was also normal. Magnetic resonance imaging (MRI) of the brain with and without contrast revealed areas of restricted diffusion in the splenium and the genu of the corpus callosum. The patient's symptoms resolved after 2 days. A follow-up MRI 2 days after the onset of symptoms revealed resolution of the callosal lesions. The patient was diagnosed clinically with migraine with prolonged aura.
CONCLUSION: MWA may be associated with reversible lesions of the corpus callosum.
© 2020 American Headache Society.

Entities:  

Keywords:  diffusion-weighted imaging; imaging; magnetic resonance imaging; migraine; splenium corpus callosum

Year:  2020        PMID: 32048282     DOI: 10.1111/head.13768

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  1 in total

Review 1.  HaNDL syndrome: a reversible cerebral vasoconstriction triggered by an infection? A case report and a case-based review.

Authors:  Giuseppe Fiamingo; Isabella Canavero; Matteo Gastaldi; Elisa Coloberti; Gabriele Buongarzone; Natascia Ghiotto; Ana Bacila; Alfredo Costa; Sabrina Ravaglia
Journal:  Eur J Med Res       Date:  2022-10-08       Impact factor: 4.981

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.